| 1. | | No longer recruiting | (1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients who Receive Neurotoxic Therapy
Conditions: Cancer; Central Nervous System Disease; Nervous System Disease; Peripheral Nervous System Disease; Progressive Multifocal Leukoencephalopathy |
| 2. | | Completed | 1-Octanol to Treat Essential Tremor
Condition: Essential Tremor |
| 3. | | Completed | 1-Octanol to Treat Essential Tremor
Condition: Essential Tremor |
| 4. | | Suspended | 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Conditions: adult Hodgkin's lymphoma; adult non-Hodgkin's lymphoma |
| 5. | | No longer recruiting | 12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.
Condition: Hepatitis C |
| 6. | | Recruiting | 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Conditions: chronic myeloproliferative disorders; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm |
| 7. | | No longer recruiting | A 12-week, multicenter, safety and dose-ranging study of 3 oral doses of TCH346 in patients with Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis |
| 8. | | Recruiting | 131MIBG to Treat Malignant Pheochromocytoma
Condition: Pheochromocytoma |
| 9. | | Recruiting | 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
Conditions: adult solid tumor; Leukemia; Lymphoma; small intestine cancer |
| 10. | | Recruiting | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors
Condition: Cancer |
| 11. | | Recruiting | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
Conditions: adult solid tumor; Leukemia; Lymphoma |
| 12. | | Recruiting | 17-DMAG to Treat Patients with Solid Tumors or Lymphomas
Conditions: Neoplasms; Lymphoma |
| 13. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Condition: Cancer |
| 14. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma |
| 15. | | Not yet recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer |
| 16. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Conditions: adult Hodgkin's lymphoma; adult T-cell leukemia and lymphoma; adult non-Hodgkin's lymphoma; adult solid tumor; Cutaneous T-Cell Lymphoma; ... |
| 17. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Von Hippel-Lindau Disease and Kidney Cancer
Conditions: stage I renal cell cancer; von Hippel-Lindau Syndrome |
| 18. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Conditions: Ewing's family of tumors; childhood rhabdomyosarcoma; childhood soft tissue sarcoma; hematopoietic and lymphoid cancer; Neuroblastoma; Osteosarcoma |
| 19. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Conditions: unspecified childhood solid tumor, protocol specific; recurrent childhood acute lymphoblastic leukemia; recurrent childhood acute myeloid leukemia; ... |
| 20. | | Recruiting | 17AAG to Treat Kidney Tumors in von Hippel-Lindau Disease
Conditions: Hippel-Lindau Disease; Kidney Cancer |
| 21. | | Recruiting | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
Conditions: refractory plasma cell neoplasm; stage III multiple myeloma; unspecified adult solid tumor, protocol specific |
| 22. | | Completed | A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS
Conditions: Cryptosporidiosis; HIV Infections |
| 23. | | Not yet recruiting | 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; peritoneal cavity cancer |
| 24. | | No longer recruiting | 3-AP and Cytarabine in Treating Patients With Hematologic Cancer
Conditions: acute leukemia; atypical chronic myeloid leukemia; chronic leukemia; myelodysplastic and myeloproliferative disease |
| 25. | | Recruiting | 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
Conditions: adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; ... |
| 26. | | Recruiting | 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Biliary Duct or Gallbladder Cancer
Conditions: unresectable extrahepatic bile duct cancer; recurrent gallbladder cancer; unresectable gallbladder cancer; recurrent extrahepatic bile duct cancer; ... |
| 27. | | Suspended | 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Conditions: stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer; recurrent pancreatic cancer |
| 28. | | Recruiting | 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
Conditions: adult acute lymphoblastic leukemia; adult acute myeloid leukemia; Chronic Myelogenous Leukemia; secondary acute myeloid leukemia |
| 29. | | Recruiting | 3-AP as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma (Cancer) of the Pancreas
Conditions: adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; ... |
| 30. | | Recruiting | 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: acute leukemia; adult acute monoblastic and acute monocytic leukemia; atypical chronic myeloid leukemia; chronic leukemia; ... |
| 31. | | Recruiting | 3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma
Conditions: recurrent renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer |
| 32. | | Recruiting | 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Conditions: recurrent esophageal cancer; stage IV esophageal cancer; Adenocarcinoma of the Esophagus |
| 33. | | No longer recruiting | 4'-Iodo-4'-deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Condition: primary systemic amyloidosis |
| 34. | | Recruiting | 4-PBA: Will it increase the level of Alpha 1-Antitrypsin(AAT) in persons with AAT deficiency?
Condition: alpha 1-Antitrypsin Deficiency |
| 35. | | Completed | A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients
Condition: Multiple Sclerosis |
| 36. | | Completed | 5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
Condition: Beta Thalassemia |
| 37. | | Completed | 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
Conditions: refractory chronic lymphocytic leukemia; T-cell chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia |
| 38. | | No longer recruiting | 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Conditions: Leukemia; Lymphoma; Multiple Myeloma |
| 39. | | No longer recruiting | 506U78 in Treating Patients With Lymphoma
Conditions: Leukemia; Lymphoma |
| 40. | | Suspended | 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia
Conditions: recurrent adult acute lymphoblastic leukemia; L1 adult acute lymphoblastic leukemia; L2 adult acute lymphoblastic leukemia; ... |
| 41. | | No longer recruiting | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
Conditions: recurrent cutaneous T-cell lymphoma; recurrent mycosis fungoides/Sezary syndrome |
| 42. | | No longer recruiting | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; recurrent adult T-cell leukemia/lymphoma; angioimmunoblastic T-cell lymphoma; ... |
| 43. | | No longer recruiting | 506U78 in Treating Patients With Refractory Hematologic Cancer
Conditions: recurrent childhood lymphoblastic lymphoma; T-cell childhood acute lymphoblastic leukemia; recurrent childhood acute lymphoblastic leukemia |
| 44. | | No longer recruiting | 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Conditions: recurrent adult lymphoblastic lymphoma; recurrent adult T-cell leukemia/lymphoma; recurrent childhood lymphoblastic lymphoma; ... |
| 45. | | Recruiting | 506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Conditions: recurrent adult acute lymphoblastic leukemia; T-cell adult acute lymphoblastic leukemia; recurrent adult lymphoblastic lymphoma |
| 46. | | No longer recruiting | 6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Colorectal Cancer
Conditions: recurrent colon cancer; Stage IV rectal cancer; adenocarcinoma of the colon; adenocarcinoma of the rectum; recurrent rectal cancer; ... |
| 47. | | Completed | 6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer
Conditions: Stage IV Renal Cell Cancer; recurrent renal cell cancer |
| 48. | | No longer recruiting | 6-Hydroxymethylacylfulvene in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Conditions: recurrent colon cancer; adenocarcinoma of the rectum; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer; ... |
| 49. | | Completed | 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
Conditions: Previously Treated Myelodysplastic Syndrome; secondary myelodysplastic syndrome; recurrent adult acute myeloid leukemia; ... |
| 50. | | No longer recruiting | 6-Hydroxymethylacylfulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer
Conditions: recurrent pancreatic cancer; stage III pancreatic cancer; stage IV pancreatic cancer; adenocarcinoma of the pancreas |
